Summit Presents New
Summit Presents New 24-Week Analyses from PhaseOut DMD at the 2018 American Academy of Neurology Annual Meeting
April 20, 2018 07:00 ET | Summit Therapeutics plc
Data show correlation between decreases in muscle damage and reduction in muscle inflammation in patients treated with ezutromid OXFORD, United Kingdom and CAMBRIDGE, Mass., April 20, 2018 (GLOBE...